Clinical Trial Update: A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study investigating Tolododekin Alfa (ANK-101) in renal allograft recipients with high-risk cutaneous squamous cell carcinoma, status not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Renal Transplant

Drugs mentioned

• Tolododekin Alfa (ANK-101)

Snippet

Sponsor: Ankyra Therapeutics, Inc | Conditions: Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant | Phase 1 | Status: NOT_YET_RECRUITING